Ihara T, Kamiya H, Matsuda T, Shimizu S, Nishi H, Inamochi H, Taki N, Suzuki M, Kojima M, Kawasaki H
Department of Pediatrics, Mie National Hospital.
Jpn J Antibiot. 1991 Nov;44(11):1259-64.
To evaluate pharmacokinetics and clinical efficacy of flomoxef (6315-S, FMOX) in neonates, FMOX was administered to 21 neonates. With 20 mg/kg and 40 mg/kg of intravenous drip-infusion of FMOX 60 minutes, half lives (T 1/2's) was 64.9 minutes and 130.3 minutes, respectively, and when 20 mg/kg of FMOX was infused intravenously to 2 cases, half lives were 70.8 minutes and 110.1 minutes, respectively. When 45-100 mg/kg of FMOX was administered to 17 neonates with infections (pneumonia 8, sepsis 1, sepsis suspected 2, intrauterine infection 2, urinary tract infection 2, omphalitis 2), the efficacy rate was 88.2% (15 of 17). No adverse reactions were observed clinically in the 21 neonates. Transient elevation of eosinophilia was observed in 1 case and transient elevation of S-GOT and S-GPT 1 in another. These results suggest that FMOX is an effective and safe antibiotic to use in neonates.
为评估氟莫西（6315-S，FMOX）在新生儿中的药代动力学及临床疗效，对21例新生儿给予了FMOX。分别以20mg/kg和40mg/kg静脉滴注FMOX 60分钟，半衰期（T1/2）分别为64.9分钟和130.3分钟，对2例以20mg/kg静脉滴注FMOX时，半衰期分别为70.8分钟和110.1分钟。对17例感染新生儿（肺炎8例、败血症1例、疑似败血症2例、宫内感染2例、尿路感染2例、脐炎2例）给予45 - 100mg/kg的FMOX，有效率为88.2%（17例中的15例）。21例新生儿临床未观察到不良反应。1例观察到嗜酸性粒细胞短暂升高，另1例观察到谷草转氨酶（S-GOT）和谷丙转氨酶（S-GPT）短暂升高。这些结果表明FMOX是一种用于新生儿的有效且安全的抗生素。
